Welcome to our dedicated page for Pelthos Therapeutics SEC filings (Ticker: PTHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pelthos Therapeutics Inc. (PTHS) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret them. As a Nevada-incorporated biopharmaceutical company listed on the NYSE American, Pelthos files a range of documents with the U.S. Securities and Exchange Commission that describe its business, governance, and financial obligations.
Key filings include Form 8-K current reports, where Pelthos discloses material events such as financing transactions, product acquisitions, and governance changes. Recent 8-K filings describe a senior secured term loan facility with Horizon Technology Finance Corporation intended to support commercialization of ZELSUVMI and the launches of Xepi and Xeglyze, an asset purchase agreement for the Xeglyze head lice treatment, and a securities purchase agreement for senior secured convertible notes used to fund the acquisition and planned relaunch of Xepi and to accelerate ZELSUVMI commercialization.
Other 8-K items and the company’s definitive proxy statement on Schedule 14A provide detail on board composition, director compensation policies, annual meeting proposals, and shareholder voting results. These documents outline Pelthos’ governance structure, committee responsibilities, and the terms under which directors and executives are compensated and indemnified.
On Stock Titan, investors can review Pelthos’ periodic reports (such as Forms 10-K and 10-Q when filed) for information on revenue from ZELSUVMI, operating expenses, cash position, and risk factors related to its commercial dermatology portfolio and financing arrangements. Form 4 and related insider transaction reports, when available, show equity dealings by directors and officers, offering additional insight into insider alignment.
AI-driven summaries on this page highlight the most important points from lengthy filings, such as covenants in loan agreements, conversion terms in convertible notes, and implications of mergers and name changes. Real-time updates from EDGAR ensure that new Pelthos filings—whether related to financings, acquisitions, or governance—are quickly reflected, while the AI layer helps users understand how each document fits into the company’s broader strategy around ZELSUVMI, Xepi, and Xeglyze.
Pelthos Therapeutics Inc. expanded its Board of Directors from seven to eight members and appointed Andrew J. Einhorn as a new independent director. Einhorn, an experienced biotech and pharmaceutical finance executive, will serve until the company’s 2026 annual meeting of shareholders. Effective December 23, 2025, he joined the Audit Committee and the Compensation Committee. For his board service, he will receive standard non-employee director compensation and an equity grant of 12,000 restricted stock units, each representing one share of common stock, which will vest on January 1, 2027. The company also entered into a standard indemnification agreement with him and issued a press release announcing his appointment.
Pelthos Therapeutics Inc. reported insider activity involving a senior secured convertible note held by a 10% owner and director-by-deputization. On November 6, 2025, Pelthos issued a
At the December 17, 2025 annual shareholder meeting, shareholders approved waiving NYSE American rules limiting the number of shares issuable in this private placement. As a result, the conversion price of the note was reduced from
Pelthos Therapeutics Inc. reported the results of its 2025 Annual Meeting of Stockholders held on December 17, 2025. As of the November 24, 2025 record date, 3,086,681 common shares were outstanding and entitled to vote, and holders representing 2,528,857 votes were present, constituting a quorum.
Stockholders elected seven directors to serve until the 2026 annual meeting, approved waiving the NYSE American limit on the number of common shares that may be issued to holders of the company’s senior secured convertible notes, and ratified CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Pelthos Therapeutics Inc. director Matthew Pauls reported equity transactions in a Form 4. On July 2, 2025 and October 2, 2025, restricted stock units (RSUs) previously granted to him vested and were converted into 8,493 and 2,123 shares of common stock, respectively, at a price of $0 per share, reflecting the nature of RSU settlements. These vestings are part of a 25,478-RSU grant made on July 2, 2025, with one-third vesting immediately and the rest quarterly over two years.
On December 10, 2025, he made a gift of 9,542 shares of common stock to the GP 2024 Trust for no consideration, reducing his directly held common stock to 1,074 shares. Pauls states he is not a trustee, does not control voting or investment decisions for the trust, and disclaims beneficial ownership of those gifted shares except for any pecuniary interest. After these transactions, he also reports continued holdings of unvested or outstanding RSUs.
Pelthos Therapeutics Inc. director reports stock sales through entities
Director Ezra M. Friedberg reported several open market sales of Pelthos Therapeutics Inc. (PTHS) common stock on 11/25/2025. Through Balmoral Financial Group LLC, he reported multiple sale transactions of common stock at prices ranging from $28.00 to $28.50 per share, including individual trades of 5,999 shares at $28.00, 2,000 shares at $28.135, 1 share at $28.50, and 2,000 shares at $28.005.
Following these transactions, the filing shows 30,000 shares of common stock beneficially owned indirectly through Balmoral Financial Group LLC, 40,000 shares indirectly through Key Recovery Group LLC, and 54,573 shares held directly. The filing notes that Mr. Friedberg is the manager of both Balmoral and Key and may be deemed to beneficially own the shares they hold, while he disclaims beneficial ownership except to the extent of his pecuniary interest.
Pelthos Therapeutics Inc. (PTHS) has called a virtual 2025 annual shareholder meeting for December 17, 2025. Shareholders will vote to elect seven directors, approve or reject a waiver of the NYSE American 20% “Exchange Cap” tied to issuances under the company’s senior secured convertible notes, and ratify the appointment of CBIZ CPAs P.C. as independent auditors for 2025.
As of the November 24, 2025 record date, Pelthos had 3,086,681 shares of common stock outstanding. Large shareholders include Ligand Pharmaceuticals and 3i LP, each subject to ownership limits on converting preferred stock. The proxy also describes a significantly expanded 2023 equity incentive plan authorizing up to 2,400,000 shares for employee, director, and consultant awards, and outlines new post‑merger employment and equity packages for key executives.
Ikarian Capital, LLC and Neil Shahrestani filed Amendment No. 1 to Schedule 13G reporting beneficial ownership of 186,408 shares of Pelthos Therapeutics (PTHS) common stock, representing 6.1% of the class. The percentage is based on 3,061,681 shares outstanding as of November 7, 2025.
The filing shows shared voting and dispositive power over 186,408 shares and no sole voting or dispositive power. The date of event triggering the filing is September 30, 2025. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Murchinson Ltd. and Marc Bistricer filed a Schedule 13G reporting beneficial ownership of Pelthos Therapeutics Inc. common stock. They report 280,000 shares, representing 9.1% of the class, with shared voting power and shared dispositive power over 280,000 shares and no sole power over any shares.
The filing identifies the securities as Pelthos Therapeutics Inc. common stock (CUSIP 171126204). The percentage is based on the issuer’s disclosure that 3,090,729 shares were outstanding as of September 30, 2025. Shares are held by one or more funds advised or sub‑advised by Murchinson Ltd., and both the Adviser and Mr. Bistricer state they may be deemed to beneficially own the reported shares, while disclaiming beneficial ownership except to the extent of their pecuniary interest.
Pelthos Therapeutics Inc. filed a current report to let investors know it has released a press release with its financial results for the three and nine months ended September 30, 2025, and an update on its operations. The press release is included as Exhibit 99.1.
The company states that this earnings information and the exhibit are being "furnished" rather than "filed," which affects how they are treated under securities laws. The same information is also referenced for Regulation FD disclosure, signaling that Pelthos is using the press release and this report to provide broad, simultaneous access to its latest quarterly and year‑to‑date results.
Pelthos Therapeutics Inc. reported Q3 2025 results following its July 1 merger with LNHC and commercial launch of ZELSUVMI. Revenue reached $7.4 million, all generated in the quarter after launch. The company recorded a net loss of $16.2 million for Q3 and $21.7 million for the nine months ended September 30, 2025.
Cash and cash equivalents were $14.2 million as of September 30, 2025, with working capital of $25.0 million. Management disclosed “substantial doubt” about the ability to continue as a going concern, citing expected commercialization, manufacturing, and development costs. Total assets rose to $126.4 million, including $32.5 million of net definite-lived intangibles and $30.6 million of goodwill from the LNHC acquisition. SG&A was $19.6 million and cost of goods sold $2.3 million in Q3.
The company completed a PIPE concurrent with the merger, issuing 50,100 Series A preferred shares for gross proceeds of $50.1 million and net proceeds of $27.4 million after settlements; 23,810 preferred shares converted into 2,381,000 common shares. Common shares outstanding were 3,061,681 as of November 7, 2025.